ThyroidPrint®: clinical utility for indeterminate thyroid cytology.
Olmos R, Domínguez JM, Vargas-Salas S, Mosso L, Fardella CE, González G, Baudrand R, Guarda F, Valenzuela F, Arteaga E, Forenzano P, Nilo F, Lustig N, Martínez A, López JM, Cruz F, Loyola S, Leon A, Droppelmann N, Montero P, Domínguez F, Camus M, Solar A, Zoroquiain P, Roa JC, Muñoz E, Bruce E, Gajardo R, Miranda G, Riquelme F, Mena N, González HE.
Olmos R, et al. Among authors: lopez jm.
Endocr Relat Cancer. 2023 Oct 6;30(11):e220409. doi: 10.1530/ERC-22-0409. Print 2023 Nov 1.
Endocr Relat Cancer. 2023.
PMID: 37671897
Free PMC article.
Molecular testing was performed in 155 of 244 ITN (63.5%), of which 104 were classified as benign (BCR of 67.1%). After a median follow-up of 15 months, 103 of 104 (99.0%) patients with a benign ThyroidPrint remained under surveillance and one patient underwent surgery whi …
Molecular testing was performed in 155 of 244 ITN (63.5%), of which 104 were classified as benign (BCR of 67.1%). After a median follow-up o …